Ultrasound Molecular Imaging of Bladder Cancer via Extradomain B Fibronectin-Targeted Biosynthetic GVs

References

• Hernot S, Klibanov AL. Microbubbles in ultrasound-triggered drug and gene delivery. Adv Drug Deliv Rev. 2008;60(10):1153–1166. doi:10.1016/j.addr.2008.03.005
   PubMed Web of Science ®Google Scholar
• Hussain T, Nguyen QT. Molecular imaging for cancer diagnosis and surgery. Adv Drug Deliv Rev. 2014;66:90–100. doi:10.1016/j.addr.2013.09.007
   PubMed Web of Science ®Google Scholar
• Abou-Elkacem L, Bachawal SV, Willmann JK. Ultrasound molecular imaging: moving toward clinical translation. Eur J Radiol. 2015;84(9):1685–1693. doi:10.1016/j.ejrad.2015.03.016
   PubMed Web of Science ®Google Scholar
• van Rooij T, Daeichin V, Skachkov I, de Jong N, Kooiman K. Targeted ultrasound contrast agents for ultrasound molecular imaging and therapy. Int J Hyperthermia. 2015;31(2):90–106. doi:10.3109/02656736.2014.997809
   PubMed Web of Science ®Google Scholar
• Xing Z, Wang J, Ke H, et al. The fabrication of novel nanobubble ultrasound contrast agent for potential tumor imaging. Nanotechnology. 2010;21(14):145607. doi:10.1088/0957-4484/21/14/145607
   PubMed Web of Science ®Google Scholar
• Marxer EE, Brussler J, Becker A, et al. Development and characterization of new nanoscaled ultrasound active lipid dispersions as contrast agents. Eur J Pharm Biopharm. 2011;77(3):430–437. doi:10.1016/j.ejpb.2010.12.007
   PubMed Web of Science ®Google Scholar
• Kim M, Lee JH, Kim SE, Kang SS, Tae G. Nanosized ultrasound enhanced-contrast agent for in vivo tumor imaging via intravenous injection. ACS Appl Mater Interfaces. 2016;8(13):8409–8418. doi:10.1021/acsami.6b02115
   PubMed Web of Science ®Google Scholar
• Zhou QL, Chen ZY, Wang YX, Yang F, Lin Y, Liao YY. Ultrasound-mediated local drug and gene delivery using nanocarriers. Biomed Res Int. 2014;2014:963891. doi:10.1155/2014/963891
   PubMed Web of Science ®Google Scholar
• Wei M, Lai M, Zhang J, Pei X, Yan F. Biosynthetic gas vesicles from halobacteria NRC-1: a potential ultrasound contrast agent for tumor imaging. Pharmaceutics. 2022;14(6):1198. doi:10.3390/pharmaceutics14061198
   PubMed Web of Science ®Google Scholar
• Hao Y, Li Z, Luo J, Li L, Yan F. Ultrasound molecular imaging of epithelial mesenchymal transition for evaluating tumor metastatic potential via targeted biosynthetic gas vesicles. Small. 2023;19(21):e2207940. doi:10.1002/smll.202207940
   PubMed Web of Science ®Google Scholar
• Pfeifer F. Distribution, formation and regulation of gas vesicles. Nat Rev Microbiol. 2012;10(10):705–715. doi:10.1038/nrmicro2834
   PubMed Web of Science ®Google Scholar
• Piraner DI, Farhadi A, Davis HC, et al. Going deeper: biomolecular tools for acoustic and magnetic imaging and control of cellular function. Biochemistry. 2017;56(39):5202–5209. doi:10.1021/acs.biochem.7b00443
   PubMed Web of Science ®Google Scholar
• Bourdeau RW, Lee-Gosselin A, Lakshmanan A, et al. Acoustic reporter genes for noninvasive imaging of microorganisms in mammalian hosts. Nature. 2018;553(7686):86–90. doi:10.1038/nature25021
   PubMed Web of Science ®Google Scholar
• Pfeifer F. Haloarchaea and the formation of gas vesicles. Life. 2015;5(1):385–402. doi:10.3390/life5010385
   PubMedGoogle Scholar
• Shapiro MG, Goodwill PW, Neogy A, et al. Biogenic gas nanostructures as ultrasonic molecular reporters. Nat Nanotechnol. 2014;9(4):311–316. doi:10.1038/nnano.2014.32
   PubMed Web of Science ®Google Scholar
• Walsby AE. Gas vesicles. Microbiol Rev. 1994;58(1):94–144. doi:10.1128/mr.58.1.94-144.1994
   PubMedGoogle Scholar
• Zhou Z, Lu ZR. Molecular imaging of the tumor microenvironment. Adv Drug Deliv Rev. 2017;113:24–48. doi:10.1016/j.addr.2016.07.012
   PubMed Web of Science ®Google Scholar
• Park J, Schwarzbauer JE. Mammary epithelial cell interactions with fibronectin stimulate epithelial-mesenchymal transition. Oncogene. 2014;33(13):1649–1657. doi:10.1038/onc.2013.118
   PubMed Web of Science ®Google Scholar
• Alisson-Silva F, Freire-de-lima L, Donadio JL, et al. Increase of O-glycosylated oncofetal fibronectin in high glucose-induced epithelial-mesenchymal transition of cultured human epithelial cells. PLoS One. 2013;8(4):e60471. doi:10.1371/journal.pone.0060471
   PubMed Web of Science ®Google Scholar
• Borsi L, Carnemolla B, Neri D, Zardi L. Use of human recombinant antibodies to the marker of angiogenesis ed-b in cancer therapy. Tumori. 2001;87(6):S8–10. doi:10.1177/030089160108700629
   PubMed Web of Science ®Google Scholar
• Hajitou A, Pasqualini R, Arap W. Vascular targeting: recent advances and therapeutic perspectives. Trends Cardiovasc Med. 2006;16(3):80–88. doi:10.1016/j.tcm.2006.01.003
   PubMed Web of Science ®Google Scholar
• Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–715. doi:10.1016/j.cell.2008.03.027
   PubMed Web of Science ®Google Scholar
• Han Z, Lu ZR. Targeting fibronectin for cancer imaging and therapy. J Mater Chem B. 2017;5(4):639–654. doi:10.1039/C6TB02008A
   PubMed Web of Science ®Google Scholar
• Qiao P, Ayat NR, Vaidya A, et al. Magnetic resonance molecular imaging of extradomain B fibronectin improves imaging of pancreatic cancer tumor xenografts. Front Oncol. 2020;10:586727. doi:10.3389/fonc.2020.586727
   PubMed Web of Science ®Google Scholar
• Hall RC, Ayat NR, Qiao PL, et al. Preclinical assessment of the effectiveness of magnetic resonance molecular imaging of extradomain-B fibronectin for detection and characterization of oral cancer. Mol Imaging Biol. 2020;22(6):1532–1542. doi:10.1007/s11307-020-01524-6
   PubMed Web of Science ®Google Scholar
• Han Z, Zhou Z, Shi X, et al. EDB fibronectin specific peptide for prostate cancer targeting. Bioconjug Chem. 2015;26(5):830–838. doi:10.1021/acs.bioconjchem.5b00178
   PubMed Web of Science ®Google Scholar
• Ayat NR, Qin JC, Cheng H, et al. Optimization of ZD2 peptide targeted gd(HP-DO3A) for detection and risk-stratification of prostate cancer with MRI. ACS Med Chem Lett. 2018;9(7):730–735. doi:10.1021/acsmedchemlett.8b00172
   PubMed Web of Science ®Google Scholar
• Ayat NR, Vaidya A, Yeung GA, et al. Effective MR molecular imaging of triple negative breast cancer with an EDB-fibronectin-specific contrast agent at reduced doses. Front Oncol. 2019;9:1351. doi:10.3389/fonc.2019.01351
   PubMed Web of Science ®Google Scholar
• Han Z, Li Y, Roelle S, et al. Targeted contrast agent specific to an oncoprotein in tumor microenvironment with the potential for detection and risk stratification of prostate cancer with MRI. Bioconjug Chem. 2017;28(4):1031–1040. doi:10.1021/acs.bioconjchem.6b00719
   PubMed Web of Science ®Google Scholar
• Ye XX, Zhao YY, Wang Q, et al. EDB fibronectin-specific SPECT probe (99m)Tc-HYNIC-ZD2 for breast cancer detection. ACS Omega. 2017;2(6):2459–2468. doi:10.1021/acsomega.7b00226
   PubMed Web of Science ®Google Scholar
• Han Z, Wu X, Roelle S, Chen C, Schiemann WP, Lu ZR. Author correction: targeted gadofullerene for sensitive magnetic resonance imaging and risk-stratification of breast cancer. Nat Commun. 2018;9(1):153. doi:10.1038/s41467-017-02302-9
   PubMedGoogle Scholar
• Yao AI, Facciotti MT. Regulatory multidimensionality of gas vesicle biogenesis in Halobacterium salinarum NRC-1. Archaea. 2011;2011:716456. doi:10.1155/2011/716456
   PubMed Web of Science ®Google Scholar
• Lakshmanan A, Lu GJ, Farhadi A, et al. Preparation of biogenic gas vesicle nanostructures for use as contrast agents for ultrasound and MRI. Nat Protoc. 2017;12(10):2050–2080. doi:10.1038/nprot.2017.081
   PubMed Web of Science ®Google Scholar
• Lieverse RIY, Marcus D, van der Wiel AMA, et al. Human fibronectin extra domain B as a biomarker for targeted therapy in cancer. Mol Oncol. 2020;14(7):1555–1568. doi:10.1002/1878-0261.12705
   PubMed Web of Science ®Google Scholar
• Pini A, Viti F, Santucci A, et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem. 1998;273(34):21769–21776. doi:10.1074/jbc.273.34.21769
   PubMed Web of Science ®Google Scholar
• Mohlmann S, Bringmann P, Greven S, Harrenga A. Site-specific modification of ED-B-targeting antibody using intein-fusion technology. BMC Biotechnol. 2011;11:76. doi:10.1186/1472-6750-11-76
   PubMed Web of Science ®Google Scholar
• Danielli R, Patuzzo R, Di Giacomo AM, et al. Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a Phase II study. Cancer Immunol Immunother. 2015;64(8):999–1009. doi:10.1007/s00262-015-1704-6
   PubMed Web of Science ®Google Scholar
• Rekers NH, Olivo Pimentel V, Yaromina A, et al. The immunocytokine L19-IL2: an interplay between radiotherapy and long-lasting systemic anti-tumour immune responses. Oncoimmunology. 2018;7(4):e1414119. doi:10.1080/2162402X.2017.1414119
   PubMed Web of Science ®Google Scholar
• Zegers CM, Rekers NH, Quaden DH, et al. Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects. Clin Cancer Res. 2015;21(5):1151–1160. doi:10.1158/1078-0432.CCR-14-2676
   PubMed Web of Science ®Google Scholar
• Borsi L, Balza E, Bestagno M, et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer. 2002;102(1):75–85. doi:10.1002/ijc.10662
   PubMed Web of Science ®Google Scholar
• Steiner M, Neri D. Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin Cancer Res. 2011;17(20):6406–6416. doi:10.1158/1078-0432.CCR-11-0483
   PubMed Web of Science ®Google Scholar
• Tijink BM, Perk LR, Budde M, et al. (124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy. Eur J Nucl Med Mol Imaging. 2009;36(8):1235–1244. doi:10.1007/s00259-009-1096-y
   PubMed Web of Science ®Google Scholar
• Menrad A, Menssen HD. ED-B fibronectin as a target for antibody-based cancer treatments. Expert Opin Ther Targets. 2005;9(3):491–500. doi:10.1517/14728222.9.3.491
   PubMed Web of Science ®Google Scholar
• Ventura E, Balza E, Borsi L, et al. Selective targeted delivery of the TNF-alpha receptor p75 and uteroglobin to the vasculature of inflamed tissues: a preliminary report. BMC Biotechnol. 2011;11:104. doi:10.1186/1472-6750-11-104
   PubMed Web of Science ®Google Scholar
• Viti F, Tarli L, Giovannoni L, Zardi L, Neri D. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res. 1999;59(2):347–352.
   PubMed Web of Science ®Google Scholar
• Wang Y, Fu M, Yang Y, et al. Modification of PEG reduces the immunogenicity of biosynthetic gas vesicles. Front Bioeng Biotechnol. 2023;11:1128268. doi:10.3389/fbioe.2023.1128268
   PubMed Web of Science ®Google Scholar